Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811529 | 0.83 | GABRA1 (0.42) | ALDH1A1TAAR1 | |
| SCHEMBL1290396 | 0.83 | ALDH1A1 (0.43) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL79270 | 0.79 | ALDH1A1 (0.41) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL3119523 | 0.79 | ALDH1A1 (0.48) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL3789998 | 0.79 | ALDH1A1 (0.48) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL8090789 | 0.78 | GABRA1 (0.52) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL14142844 | 0.77 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL5066645 | 0.77 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL11006111 | 0.77 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAHPGDALOX12 | |
| SCHEMBL92967 | 0.77 | PDCD1 (0.53) | ALDH1A1PNMTLMNAHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108634-B | Imidazopyridazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2020-09-15 | — | — | CN | disclosed |
| WO-2020119592-A1 | NOVEL THREE-RING FUSED STRUCTURE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2020-06-18 | — | — | WO | disclosed |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2020067593-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 희성소재(주) | 2020-04-02 | — | — | WO | disclosed |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2019-08-22 | — | — | US | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3170813-B1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10087187-B2 | Imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2018-09-20 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20050154007-A1 | New compounds | AMIN KOSRAT (SE) | 2005-07-14 | — | — | US | disclosed |
| US-6790960-B2 | Compounds | ASTRAZENECA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-1411056-A2 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation | AstraZeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| WO-2002057257-A1 | CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| CN-1329613-A | novel compounds | ASTRAZENECA AB (SE) | 2002-01-02 | — | — | CN | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | ALDH1A1 1399/4885PNMT 4195/4885LMNA 4594/4885 |
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | ALDH1A1 1375/4885PNMT 1984/4885LMNA 4753/4885 |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | ALDH1A1 1375/4885PNMT 1984/4885LMNA 4753/4885 |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | ALDH1A1 1375/4885PNMT 1984/4885LMNA 4753/4885 |
| US-10087187-B2 | Imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | ALDH1A1 1344/4885PNMT 3688/4885LMNA 3691/4885 |
| US-20050154007-A1 | New compounds | SLC10A2, GIPR, FABP6 | ALDH1A1 1838/4885PNMT 4132/4885LMNA 4580/4885 |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PIK3CD, PI4KA | ALDH1A1 1375/4885PNMT 1984/4885LMNA 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.